Cognition Therapeutics

Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small molecule therapeutics targeting the underlying biology of neurodegenerative diseases. The company's pipeline is centered on its proprietary Sigma-2 receptor platform, which it leverages to identify compounds that modulate protein misfolding and cellular stress pathways implicated in conditions like Alzheimer's disease. Headquartered in Purchase, New York, the company is publicly traded on the NASDAQ under the ticker symbol CGTX.

Company Overview

The company was founded to advance discoveries originating from research conducted at Vanderbilt University and the University of Pittsburgh. Its scientific foundation is built upon the work of researchers in the fields of neuropharmacology and medicinal chemistry. The leadership team includes individuals with extensive experience in the pharmaceutical industry, particularly in central nervous system drug development and clinical trial design. Its corporate strategy involves advancing its lead candidates through rigorous Phase 2 and Phase 3 studies to demonstrate safety and efficacy.

Drug Candidates

The lead investigational product is **CT1812**, an orally administered, brain-penetrant small molecule that selectively and reversibly modulates the Sigma-2 receptor, a component of the PGRMC1 complex implicated in cellular homeostasis. This candidate is designed to protect neurons from the toxic effects of amyloid beta oligomers and tau pathology by preventing their binding to neuronal synapses. A second candidate, **CT2718**, is a follow-on molecule from the same platform, also targeting the Sigma-2 receptor but with a distinct pharmacological profile intended for potential use in other proteinopathies such as Parkinson's disease and dementia with Lewy bodies.

Clinical Trials

The clinical development program for CT1812 has included several studies. The **SHINE** study is a Phase 2 trial evaluating the candidate in patients with mild-to-moderate Alzheimer's disease, assessing effects on cognitive function and biomarkers. The **SHIMMER** study is a Phase 2 trial investigating CT1812 in patients with dementia with Lewy bodies. Earlier phase studies, such as the **COG0201** trial, provided initial data on pharmacokinetics, tolerability, and target engagement in healthy volunteers and Alzheimer's patients. These trials are often conducted at major academic medical centers across the United States.

Scientific Approach

The core hypothesis is that the Sigma-2 receptor plays a key role in the cellular response to neurotoxic proteins associated with neurodegeneration. By modulating this receptor, its drug candidates aim to disrupt the binding of pathological proteins like amyloid beta oligomers to neuronal receptors, thereby preserving synaptic function. This mechanism is distinct from amyloid-clearing antibodies like lecanemab and aducanumab. The company utilizes techniques including positron emission tomography imaging and cerebrospinal fluid analysis to measure target engagement and biological effects in its trials.

Collaborations and Partnerships

The company has established several key collaborations to advance its research. It has a longstanding partnership with the Alzheimer's Disease Cooperative Study, a consortium coordinated by the University of California, San Diego, for clinical trial execution. It has also collaborated with the Michael J. Fox Foundation for Parkinson's disease research. Furthermore, it has entered into agreements with contract research organizations for clinical operations and with specialized firms for the manufacturing of its drug substances under Good Manufacturing Practice standards.

Financial Information

As a publicly traded entity on the NASDAQ, its operations are funded through a combination of equity financing, including public offerings, and grants from organizations like the National Institutes of Health. Its financial resources are primarily allocated toward research and development costs associated with its ongoing clinical trial programs. Like many clinical-stage biotechnology companies, it has incurred net losses as it advances its pipeline, with its financial viability dependent on successful trial outcomes and future potential collaborations or licensing agreements with larger pharmaceutical partners.

Category:Biopharmaceutical companies of the United States Category:Companies listed on NASDAQ